Use of botulinum toxin A in pelvic floor dysfunctions in the elderly: A review
| Autor: | X, Biardeau, R, Haddad, C, Chesnel, A, Charlanes, C, Hentzen, N, Turmel, S, Campagne, G, Capon, B, Fatton, X, Gamé, C, Jeandel, J, Kerdraon, P, Mares, M, Mezzadri, A-C, Petit, B, Peyronnet, J-M, Soler, C, Thuillier, X, Deffieux, G, Robain, G, Amarenco, P, Manceau |
|---|---|
| Přispěvatelé: | Service d'Urologie, andrologie et transplantation rénale [CHRU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Rothschild [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Hôpital de Rangueil, CHU Toulouse [Toulouse], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de KERPAPE [Ploemeur] (CMRRF), Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de Kerpape, Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Service de gynécologie et obstétrique [Hopital Lariboisière - Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université de Paris (UP), Centre de santé, Centre Hospitalier Universitaire [Rennes], Centre Hospitalier Universitaire [Grenoble] (CHU), CHU CLAMART, Service d'urologie [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Avicennes University Hospital |
| Jazyk: | francouzština |
| Rok vydání: | 2019 |
| Předmět: |
Benign prostatic hyperplasia
Urinary Bladder Overactive Overactive bladder [SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology Age Factors MESH: Botulinum Toxins Type A / administration & dosage Neuromuscular Agents / administration & dosage Pelvic Floor Disorders / drug therapy Neurogenic detrusor overactivity [SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics Pelvic Floor Disorders [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology Injections Urinary Bladder Neck Obstruction Neuromuscular Agents Dyschezia Fecal incontinence Humans Botulinum Toxins Type A Urinary Bladder Neurogenic Aged |
| Zdroj: | Progrès en Urologie Progrès en Urologie, Elsevier Masson, 2019, 29 (4), pp.216-225. ⟨10.1016/j.purol.2018.11.001⟩ |
| ISSN: | 1166-7087 |
| DOI: | 10.1016/j.purol.2018.11.001⟩ |
| Popis: | International audience; The present article is the final report of a multi-disciplinary meeting supported by the GRAPPPA (group for research applied to pelvic floor dysfunctions in the elderly). The objective was to conduct a comprehensive review on the role of botulinum toxin A (BonTA) in the treatment of pelvic floor dysfunctions in the elderly.Methods: The present article, written as a comprehensive review of the literature, combines data issued from the scientific literature with expert's opinions. Review of the literature was performed using the online bibliographic database MedLine (National Library of Medicine). Regarding intra-detrusor BonTA injections, only articles focusing on elderly patients (>65 yo) were included. Regarding other localizations, given the limited number of data, all articles reporting outcomes of BonTA were included, regardless of studies population age. In case of missing or insufficient data, expert's opinions were formulated.Results: Although, available data are lacking in this specific population, it appears that BonTA could be used in the non-fraily elderly patients to treat overactive bladder or even neurogenic detrusor overactivity, with a success rate comparable to younger population at 3 months (88.9% vs. 91.2%), 6 months (49.4% vs. 52.1%) and 12 months (23.1% vs. 22.3%), as well as a significant decrease in number of voids per day (11.4 vs. 5.29 P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|